HIM
CYTK icon

Hillsdale Investment Management’s Cytokinetics CYTK Stock Holding History

Hillsdale Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-6,200
Closed -$47K – 543
2013
Q3 		$47K Buy
+6,200
New +$66.5K 0.01% 412

Other funds holding CYTK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LPLP
Lansdowne Partners Limited Partnership London, United Kingdom $11.9B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Hillsdale Investment Management's CYTK Position: Q4 2013 in Review

Hillsdale Investment Management sold out of Cytokinetics (CYTK) in Q4 2013, closing a stake of 6,200 shares — an estimated $47K sold.

Hillsdale Investment Management first reported a position in CYTK in Q3 2013 and held it in 1 quarter. The position peaked at $47K in Q3 2013. 95 funds tracked by Wall St. Rank hold CYTK as of Q4 2013.

  • Hillsdale Investment Management reported no remaining Cytokinetics position as of Q4 2013 after selling out during the quarter.
  • Hillsdale Investment Management sold 6,200 Cytokinetics shares in Q4 2013, an estimated $47K.
  • Hillsdale Investment Management first reported a position in Cytokinetics in Q3 2013 and held it in 1 quarter.
  • Hillsdale Investment Management's Cytokinetics position peaked at $47K in Q3 2013.
  • 95 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2013.

Based on Hillsdale Investment Management's 13F filing for Q4 2013, filed 13 Feb 2014.